Published Study Supports MyoKardia ’s Wrist-Worn Biosensor

MyoKardia’s said data on its wrist-worn digital health device was published in an article titled, “Machine Learning Detection of Obstructive Hypertrophic Cardiomyopathy (oHCM) Using a Wearable Biosensor,” in the Nature Partner Journal, Digital Medicine. The South San Francisco-based company said results from an exploratory study provided encouraging evidence of the potential for a wrist-worn biosensor to screen for obstructive hypertrophic cardiomyopathy. The study demonstrated that continuous monitoring using a wrist-worn photoplethysmography (PPG) digital health device, similar to the optical sensors that monitor heart rate on commercially available fitness trackers, revealed differences in arterial pulse wave patterns between oHCM patients and those of individuals without oHCM. MyoKardia’s proprietary machine learning algorithm identified individuals with oHCM with a sensitivity of 0.95 and a specificity of 0.98. The digital health substudy was conducted by MyoKardia as part of the company’s Phase 2 PIONEER-HCM trial of mavacamten. “Hypertrophic cardiomyopathy, or HCM, is associated with an increased risk for heart failure, stroke, and sudden death, even in asymptomatic patients. However, HCM is vastly underdiagnosed, as only approximately 15% of the estimated 1 in 500 people with HCM receive the correct diagnosis. The symptoms of HCM, such as shortness of breath, ex...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Cardiovascular Source Type: news

Related Links:

Publication date: June 2019Source: Archives of Cardiovascular Diseases Supplements, Volume 11, Issue 3Author(s): C. Heuze, L. Legrand, A. Diallo, M.L. Monin, C. Ewenczyk, R. Isnard, E. Vicaut, A. Durr, F. PoussetIntroductionFriedreich ataxia (FRDA) is a rare genetic ataxia. The causal mutation is an expanded trinucleotide repeat (GAA) in the frataxin gene. Hypertrophic cardiomyopathy in FRDA is the major cause of early death. Patients with progressive decline of the left ventricular ejection fraction (LVEF) have the worst prognosis. The aim of the study was to evaluate the prognostic value of 2D global longitudinal strain ...
Source: Archives of Cardiovascular Diseases Supplements - Category: Cardiology Source Type: research
Conclusion: These findings limit the possible roles of gene transcriptional changes in previously reported age-dependent pro-arrhythmic electrophysiologial changes observed in Pgc-1β-/- atria to an altered Ca2+-ATPase (Atp2a2) expression. This directly parallels previously reported arrhythmic mechanism associated with p21-activated kinase type 1 deficiency. This could add to contributions from the direct physiological outcomes of mitochondrial dysfunction, whether through reactive oxygen species (ROS) production or altered Ca2+ homeostasis. Introduction Atrial arrhythmias constitute a major public health probl...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
ConclusionsThis study, using two independent sources to verify vital status and cause of mortality, confirms that survival following septal myectomy is excellent. Hypertrophic cardiomyopathy was identified as the primary cause of death in less than 20%, with mortality in most patients unrelated to hypertrophic cardiomyopathy.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
In this study, we describe early outcomes of patients with apical HCM following transapical myectomy and compare survival to that of patients with hypertrophic cardiomyopathy listed for heart transplantation.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Source Type: research
Left ventricular ejection fraction (LVEF) is a commonly used index of systolic function. However, the LVEF often remains normal in patients with hypertrophic cardiomyopathy (HCM) despite disease progression until the end-stage of the disease. This is because myocardial hypertrophy results in progressive declines in ventricular capacitance and end-diastolic volume, which are accompanied by reduction in stroke volume.1-5 Accordingly, the LVEF does not correlate with functional capacity in HCM6 and is not predictive of adverse events including worsening heart failure, arrhythmias, sudden death, or appropriate implantable card...
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: Clinical Investigation Source Type: research
In conclusion, CA may be associated with a favorable long-term clinical course in HCM patients with AF.
Source: Heart and Vessels - Category: Cardiology Source Type: research
ConclusionsThe cardiovascular death and cardiovascular events are significantly increased in patients with HOCM and CAD who underwent CABG at the time of septal myectomy.
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: ORIGINAL ARTICLE Source Type: research
Abstract Some patients with hypertrophic cardiomyopathy (HCM) develop systolic dysfunction, called the dilated phase of HCM (d-HCM), which is associated with increased morbidity and mortality. We conducted a retrospective study using an HCM database to clarify the incidence, clinical characteristics, and long-term outcomes of d-HCM. We analyzed an HCM cohort consisting of 434 patients (273 with apical HCM and 161 with non-apical HCM; 18 had obstructive HCM, 16 had dilated HCM, and 127 had other HCM) diagnosed by echocardiography in our hospital between 1991 and 2010. The follow-up period was 8.4 ± 6.7 years...
Source: The Keio Journal of Medicine - Category: Universities & Medical Training Authors: Tags: Keio J Med Source Type: research
ConclusionsHere we report the case of a patient with hereditary cardiac amyloidosis associated with a Pro24Ser mutation in transthyretin, which is the first case reported in Japan. Technetium pyrophosphate scintigraphy was extremely useful for definitive diagnosis. Thus, we propose that the nuclear imaging technique should be taken into account even for an exploratory diagnosis of transthyretin cardiac amyloidosis.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Publication date: October 2018Source: Journal of the Saudi Heart Association, Volume 30, Issue 4Author(s): Sara Saleh Aldwailah, Dikra Al-Dobai, Deema Alduaiji, Shatha Naser Almutari, Azra Mahmud, Mohammad AlGhamdiIntroductionHypertrophic Cardiomyopathy (HCM), a relatively uncommon entity, is the most common form of genetic cardiovascular disorders. It is the most common cause of sudden death in the young and also heart failure which can occur at any age. While HCM is a well-described global disorder, there is paucity of data on this important clinical entity in Saudi Arabia. Therefore, the aim of this study was to explore...
Source: Journal of the Saudi Heart Association - Category: Cardiology Source Type: research
More News: Cardiology | Cardiomyopathy | Cardiovascular | Heart | Heart Failure | Hypertrophic Cardiomyopathy | Learning | Medical Devices | Sports Medicine | Stroke | Study | Universities & Medical Training